Details of the Drug

General Information of Drug (ID: DMDWZGJ)

• Drug Name: 5-hydroxy-L-tryptophan
• Synonyms: 5-hydroxytryptophan

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 220.22
  Logarithm of the Partition Coefficient (xlogp); -1.2
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 4
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property: Metabolism: The drug is metabolized via a vitamin B6 dependent reaction in nervous tissue and in the liver []
• Chemical Identifiers:
  Formula: C11H12N2O3
  IUPAC Name: (2S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid
  Canonical SMILES: C1=CC2=C(C=C1O)C(=CN2)C[C@@H](C(=O)O)N
  InChI: InChI=1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)/t9-/m0/s1
  InChIKey: LDCYZAJDBXYCGN-VIFPVBQESA-N
• Cross-matching ID:
  PubChem CID: 439280
  ChEBI ID: CHEBI:17780
  CAS Number: 4350-09-8
  DrugBank ID: DB02959
  TTD ID: D09BNS
  VARIDT ID: DR01071

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Solute carrier family 36 member 1 (SLC36A1)	TTUYIZW	S36A1_HUMAN	Inhibitor	[2]
Solute carrier family 36 member 2 (SLC36A2)	TT5U0XA	S36A2_HUMAN	Inhibitor	[3]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from 5-hydroxy-L-tryptophan (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[4]
Oliceridine	DM6MDCF	Moderate	Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Oliceridine.	Acute pain [MG31]	[5]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Levomilnacipran.	Chronic pain [MG30]	[6]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Vilazodone.	Depression [6A70-6A7Z]	[6]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Vortioxetine.	Depression [6A70-6A7Z]	[6]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Milnacipran.	Depression [6A70-6A7Z]	[7]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Desvenlafaxine.	Depression [6A70-6A7Z]	[6]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of 5-hydroxy-L-tryptophan and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[8]
Ozanimod	DMT6AM2	Moderate	Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Ozanimod.	Multiple sclerosis [8A40]	[9]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Lorcaserin.	Obesity [5B80-5B81]	[8]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Safinamide.	Parkinsonism [8A00]	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4671).
• [2] Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB J. 2005 Sep;19(11):1468-73.
• [3] Amino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2). Biochim Biophys Acta. 2011 Jan;1808(1):260-70.
• [4] Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5. [PMID: 7919561]
• [5] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
• [6] Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
• [7] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9. [PMID: 8548727]
• [8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
• [9] Jacob JE, Wagner ML, Sage JI "Safety of selegiline with cold medications." Ann Pharmacother 37 (2003): 438-41. [PMID: 12639177]